Disc Medicine, Inc. (IRON)
| Market Cap | 2.63B +96.4% |
| Revenue (ttm) | n/a |
| Net Income | -212.18M |
| EPS | -6.01 |
| Shares Out | 38.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 317,359 |
| Open | 68.32 |
| Previous Close | 68.32 |
| Day's Range | 67.11 - 69.93 |
| 52-Week Range | 40.00 - 99.50 |
| Beta | 2.54 |
| Analysts | Strong Buy |
| Price Target | 103.18 (+49.86%) |
| Earnings Date | May 11, 2026 |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for IRON stock is "Strong Buy." The 12-month stock price target is $103.18, which is an increase of 49.86% from the latest price.
News
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Disc Medicine, Inc. (“Disc Medicine" or the "Company") (NASDAQ: IRON) investors that the firm has initiated an investigatio...
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Disc Medicine, I...
Disc Medicine Transcript: Leerink Global Healthcare Conference 2026
Lead asset bitopertin is on track for phase III data in Q4 and potential resubmission by year-end, following a regulatory setback. Pipeline programs in myelofibrosis, IBD anemia, and polycythemia vera are advancing, with multiple data readouts expected in 2024-2025.
Disc Medicine Transcript: TD Cowen 46th Annual Health Care Conference
Three clinical-stage programs are advancing, with key data readouts expected by year-end. The lead EPP program targets a mid-next year launch pending phase III results and regulatory review, while strong financials and capital efficiency support ongoing development.
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route
Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for its rare disease drug after the Food and Drug Administration declined to approve the treatment under a new fast-tra...
Disc Medicine Transcript: Status update
FDA issued a CRL for bitopertin, citing insufficient evidence that PP9 reduction predicts clinical benefit, delaying approval. The phase III APOLLO trial is fully enrolled, with top-line data expected in Q4 2024, and the company remains confident in its design and regulatory alignment.
US FDA declines to approve Disc Medicine's rare disease drug
Disc Medicine said on Friday the U.S. Food and Drug Administration has declined to approve its drug to treat a rare genetic disorder, sending its shares down 31.6% to $48.90.
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for ...
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action
The U.S. Food and Drug Administration (FDA) reviewers on Thursday postponed their decision on an experimental treatment from Disc Medicine Inc. (NASDAQ: IRON) by about two weeks to Feb.10.
Disc Medicine Transcript: 44th Annual J.P. Morgan Healthcare Conference
Transitioning to a commercial-stage company, the lead program for EPP is nearing FDA approval with strong clinical data and launch readiness. Pipeline assets target large, underserved hematology markets, with pivotal trials and ex-U.S. expansion planned for 2027.
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Transcript: Status Update
Bitopertin's NDA for EPP is under priority review, with a potential launch by January 2026 and commercial preparations accelerating. RALLY-MF phase II interim data for DISC-0974 show strong, durable anemia responses across all patient groups, supporting broad applicability and a favorable safety profile. DISC-3405 advances in PV and sickle cell disease, with robust pipeline funding into 2029.
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Transcript: Jefferies London Healthcare Conference 2025
Disc Medicine is advancing three clinical programs targeting rare blood disorders, with bitopertin for EPP nearing potential FDA approval and launch, and DISC-0974 showing promising phase 2 results in myelofibrosis anemia. The company is well-funded, with $825 million to support its pipeline.
Disc Medicine Transcript: Stifel 2025 Healthcare Conference
Multiple late-stage programs are advancing, with Bidapertin's NDA under accelerated review and potential approval by early 2024. Commercial launch preparations are underway, leveraging targeted patient identification and a staged infrastructure build. Strong financial position supports execution through key milestones.
Disc Medicine Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Bitopertin is on an accelerated FDA review for EPP, with launch preparations focused on 6,000 engaged patients and a 24-rep sales force. Pipeline assets show strong clinical progress in anemia and polycythemia vera, while cash reserves of $826 million provide a runway through early 2029.
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...